Luigi Marcheselli

Modena, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

Journal: British journal of haematology

Published: May 16, 2026

Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.

Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.

Journal: British journal of haematology

Published: April 22, 2026

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

Journal: HemaSphere

Published: February 04, 2026

Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.

Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.

Journal: The New England journal of medicine

Published: December 30, 2025

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

Journal: British journal of haematology

Published: November 22, 2025

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.

Journal: Hematological oncology

Published: November 17, 2025

The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study.

The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study.

Journal: HemaSphere

Published: May 13, 2025

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study.

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study.

Journal: JCO global oncology

Published: May 05, 2025

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Journal: Haematologica

Published: April 01, 2025

Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).

Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).

Journal: British journal of haematology

Published: March 25, 2025

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.

Journal: Leukemia & lymphoma

Published: March 08, 2025

Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort Study.

Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort Study.

Journal: Hematological oncology

Published: February 11, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026